Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Axicabtagene Ciloleucel · Yescarta

Cell therapy (CAR-T) · Kills target cells, directed at CD19 · developed by Kite Pharma

Approved FDA, Oct 2017
GILD Developer
1 Registered trials

What is Axicabtagene Ciloleucel?

Axicabtagene ciloleucel is a CD19-directed genetically modified autologous T cell immunotherapy. It binds CD19-expressing cancer cells and normal B cells, with its CD28 and CD3-zeta co-stimulatory domains driving T cell activation, proliferation and killing of CD19-expressing cells. It is studied in B-cell non-Hodgkin lymphomas, including diffuse large B-cell, mantle cell and marginal zone lymphoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Yescarta
Drug type
Cell therapy (CAR-T)
Targets
CD19 (antigen)
Mechanism
Kills target cells, directed at CD19
Pathways
T cell activation and proliferation, inflammatory cytokine and chemokine secretion
Therapy area
Oncology
Developer
Kite Pharma, Inc. (GILD)
FDA status
Approved as Yescarta (October 18, 2017), BLA125643 · FDA label
UNII
U2I8T43Y7R

✅ FDA-approved uses

From the indications section of the FDA label (version of Aug 6, 2026). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07763210 Phase 2 Non-hodgkin Lymphoma Recruiting GILD

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Non-hodgkin LymphomaRecurrent Diffuse Large B-Cell LymphomaRecurrent Mantle Cell LymphomaRefractory Mantle Cell LymphomaRefractory Marginal Zone Lymphoma

Other drugs acting on CD19

Blinatumomab FDA approved Inebilizumab FDA approved Loncastuximab tesirine FDA approved Budoprutug Phase 1/2 MK-1045 Phase 2/3

More from Kite Pharma

Bictegravir FDA approved Brexucabtagene Autoleucel FDA approved Bulevirtide FDA approved Cobicistat FDA approved Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDA approved Emtricitabine And Tenofovir Alafenamide FDA approved Emtricitabine/Tenofovir Disoproxil FDA approved Lenacapavir FDA approved Remdesivir FDA approved Sacituzumab Govitecan FDA approved Seladelpar FDA approved Tenofovir Disoproxil FDA approved

Sources

Updated Oct 8, 2026. Something wrong or missing? Report it on the GILD page.

Follow GILD, the company behind Axicabtagene Ciloleucel

See GILD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GILD catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.